Screener Summaries Updates Institutions Sign In More Updates › Other Events › OKYO Other Events · Jul 8, 2026
OKYO Pharma LTD announced on July 8, 2026, that it received positive feedback from the U.S. Food and Drug… OKYO OKYO Pharma Ltd
OKYO Pharma LTD announced on July 8, 2026, that it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its regulatory and clinical path for urcosimod, supporting its advancement into a global Phase 3 pivotal trial for NCP. OKYO Pharma LTD is a biopharmaceutical company specializing in the development and research of ophthalmic drugs.
More from OKYO Pharma Ltd OKYO Pharma CEO to present at Stifel Healthcare Conference Nov. 10-12 Nov 5, 2026 OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain Oct 6, 2026 On July 28, 2026, Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma, purchased 3,363 ordinary shares on NASDAQ… Jul 28, 2026 OKYO Pharma Ltd announced its participation in the virtual BTIG Biotechnology Conference 2026 scheduled for July… Jul 27, 2026 Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.48 per share, increasing his… Jul 23, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
